Literatur
-
1
Steering Committee of the Physicians’ Health Study Research Group .
Final report on the aspirin component of the ongoing Physicians’ Health Study.
N Engl J Med.
1989;
321
129-135
-
2
Anderson G D.
Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics.
J Womens Health (Larchmt ).
2005;
14
19-29
-
3
Blaustein M P, Robinson S W, Gottlieb S S, Balke C W, Hamlyn J M.
Sex, digitalis, and the sodium pump.
Mol Interv.
2003;
3
68-72
-
4
Chen M L, Lee S C, Ng M J, Schuirmann D J, Lesko L J, Williams R L.
Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
Clin Pharmacol Ther.
2000;
68
510-521
-
5
Craft R M.
Sex differences in opioid analgesia: „from mouse to man”.
Clin J Pain.
2003;
19
175-186
-
6
Drici M D, Clement N.
Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drug Saf.
2001;
24
575-585
-
7
Evans R S, Lloyd J F, Stoddard G J, Nebeker J R, Samore M H.
Risk factors for adverse drug events: a 10-year analysis.
Ann Pharmacother.
2005;
39
1161-1168
-
8
Harris D J, Douglas P S.
Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute.
N Engl J Med.
2000;
343
475-480
-
9
Kando J C, Yonkers K A, Cole J O.
Gender as a risk factor for adverse events to medications.
Drugs.
1995;
50
1-6
-
10
Kornstein S G, Schatzberg A F, Thase M E, Yonkers K A, McCullough J P, Keitner G I, Gelenberg A J, Davis S M, Harrison W M, Keller M B.
Gender differences in treatment response to sertraline versus imipramine in chronic depression.
Am J Psychiatry.
2000;
157
1445-1452
-
11
Krecic-Shepard M E, Barnas C R, Slimko J, Jones M P, Schwartz J B.
Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans.
J Clin Pharmacol.
2000;
40
219-230
-
12
Krecic-Shepard M E, Park K, Barnas C, Slimko J, Kerwin D R, Schwartz J B.
Race and sex influence clearance of nifedipine: results of a population study.
Clin Pharmacol Ther.
2000;
68
130-142
-
13
Levin R I.
The puzzle of aspirin and sex.
N Engl J Med.
2005;
352
1366-1368
-
14
Luzier A B, Killian A, Wilton J H, Wilson M F, Forrest A, Kazierad D J.
Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Clin Pharmacol Ther.
1999;
66
594-601
-
15
Makkar R R, Fromm B S, Steinman R T, Meissner M D, Lehmann M H.
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
JAMA.
1993;
270
2590-2597
-
16
Martin R M, Biswas P N, Freemantle S N, Pearce G L, Mann R D.
Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.
Br J Clin Pharmacol.
1998;
46
505-511
-
17
Meibohm B, Beierle I, Derendorf H.
How important are gender differences in pharmacokinetics?.
Clin Pharmacokinet.
2002;
41
329-342
-
18
Pleym H, Spigset O, Kharasch E D, Dale O.
Gender differences in drug effects: implications for anesthesiologists.
Acta Anaesthesiol Scand.
2003;
47
241-259
-
19
Rademaker M.
Do women have more adverse drug reactions?.
Am J Clin Dermatol.
2001;
2
349-351
-
20
Rathore S S, Curtis J P, Wang Y, Bristow M R, Krumholz H M.
Association of serum digoxin concentration and outcomes in patients with heart failure.
JAMA.
2003;
289
871-878
-
21
Rathore S S, Foody J M, Wang Y, Herrin J, Masoudi F A, Havranek E P, Ordin D L, Krumholz H M.
Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project.
Am Heart J.
2005;
149
121-128
-
22
Rathore S S, Wang Y, Krumholz H M.
Sex-based differences in the effect of digoxin for the treatment of heart failure.
N Engl J Med.
2002;
347
1403-1411
-
23
Ridker P M, Cook N R, Lee I M, Gordon D, Gaziano J M, Manson J E, Hennekens C H, Buring J E.
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
N Engl J Med.
2005;
352
1293-1304
-
24
Rodriguez I, Kilborn M J, Liu X K, Pezzullo J C, W oosley R L.
Drug-induced QT prolongation in women during the menstrual cycle.
JAMA.
2001;
285
1322-1326
-
25
Schmucker D L, Vesell E S.
Underrepresentation of women in clinical drug trials.
Clin Pharmacol Ther.
1993;
54
11-15
-
26
Schwartz J B.
The influence of sex on pharmacokinetics.
Clin Pharmacokinet.
2003;
42
107-121
-
27
Thurmann P A.
(Gender-related differences in pharmacokinetics and pharmacodynamics).
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
2005;
48
536-540
-
28
Tran C, Knowles S R, Liu B A, Shear N H.
Gender differences in adverse drug reactions.
J Clin Pharmacol.
1998;
38
1003-1009
-
29
Walle T, Byington R P, Furberg C D, McIntyre K M, Vokonas P S.
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial.
Clin Pharmacol Ther.
1985;
38
509-518
-
30
Wolbold R, Klein K, Burk O, Nussler A K, Neuhaus P, Eichelbaum M, Schwab M, Zanger U M.
Sex is a major determinant of CYP3A4 expression in human liver.
Hepatology.
2003;
38
978-988
Prof. Dr. med. Ursula Ravens
Institut für Pharmakologie und Toxikologie
Fetscherstraße 74
01307 Dresden
Telefon: 0351/4586300
Fax: 0351/4586315
eMail: ravens@rcs.urz.tu-dresden.de
